Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Provention Bio, Inc. (PRVB : NSDQ)

• Company Description    Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The company's product pipeline consists of PRV-031, PRV-6527, PRV-300, PRV-3279 and PRV-101 which are in clinical stage. Provention Bio, Inc. is based in NJ, United States. Number of Employees: 82

• Price / Volume Information    Yesterday's Closing Price: $3.91 Daily Weekly Monthly 20 Day Moving Average: 609,595 shares Shares Outstanding: 64.04 (millions) Market Capitalization: $250.40 (millions) Beta: 2.74 52 Week High: $11.49 52 Week Low: $3.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.30% -21.50% 12 Week -38.42% -32.30% Year To Date -30.43% -14.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 55 Broad Street 2nd Floor - Red Bank,NJ 07701 USA ph: 908-336-0360 fax: - rdoody@proventionbio.com http://www.proventionbio.com

• General Corporate Information    Officers Ashleigh Palmer - Chief Executive Officer and Director Thierry Chauche - Chief Financial Officer Jeffrey Bluestone - Director Avery Catlin - Director Sean Doherty - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74374N102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 64.04 Most Recent Split Date: (:1) Beta: 2.74 Market Capitalization: $250.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.63 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 32.69% vs. Previous Quarter: 14.63% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -19.11% ROE 03/31/22 - -83.66 12/31/21 - -78.01 09/30/21 - -82.57 ROA 03/31/22 - -69.39 12/31/21 - -66.28 09/30/21 - -70.92 Current Ratio 03/31/22 - 3.39 12/31/21 - 4.44 09/30/21 - 7.46 Quick Ratio 03/31/22 - 3.39 12/31/21 - 4.44 09/30/21 - 7.46 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -5,671.70 12/31/21 - -8,274.70 09/30/21 - -18,020.65 Book Value 03/31/22 - 1.47 12/31/21 - 1.75 09/30/21 - 2.12 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©